Company: SCLXW
Filing Date: 2025-07-23
Form Type: 424B3
Source: 0001193125-25-163077
Chunk: 226

Company: Scilex Holding Co
Filing Date: 2025-07-23
Form: 424B3
Chunk 226
---
 no event shall this preclude or be construed to limit, reduce or negate any of Purchaser’s obligations to pay or reimburse, or Oramed’s rights to receive
reimbursement of, Oramed’s expenses pursuant to any agreement between Oramed and Purchaser or its subsidiaries (including pursuant to including in respect of legal fees to Proskauer incurred from and after the date of this
Agreement.

(d) . Purchaser’s obligation to make the payments set forth in
and (together with any interest accrued thereon pursuant to ) shall survive any termination of this Agreement pursuant to
and shall accelerate and become immediately due and payable upon any such termination of this Agreement pursuant to .

2. .

(a) . Purchaser may exercise the Option by providing written notice (email being sufficient) to Oramed
not less than three (3) Business Days prior to the date on which the applicable Warrant Purchase Closing (as defined below) is to occur; Purchaser may not exercise the Option unless and until (x) with respect to
the Initial Subject Warrants, the First Option Closing Payment (together with any interest accrued thereon) set forth in has been received by Oramed, and (y) with respect to the Final Subject Warrants,
the entire Option Fee (together with any interest accrued thereon) has been received by Oramed. If Purchaser fails to make (i) the First Option Closing Payment on or before the First Option Payment Date, Purchaser automatically and irrevocably
forfeits the

2

right to exercise the Option in its entirety and shall not have the option to purchase any Subject Warrants and (ii) the Second Option Closing Payment on or before the Second Option Payment
Date, Purchaser automatically and irrevocably forfeits the right to exercise the Option in respect of the Final Subject Warrants.

(b) . Upon Purchaser’s exercise of the applicable Option, Oramed hereby agrees to sell, transfer
and assign to Purchaser, and Purchaser agrees to purchase from Oramed, all right, title and interest in and to the Subject Warrants (free and clear of all Encumbrances (as defined below)) in exchange for an aggregate purchase price of $27,000,000.00
(the “” and the price that is equal to the Purchase Price divided by the Total Warrant Shares, the “” ), to be paid as follows (such purchase and sale of the Subject
Warrants,